Research Summary

Analyzed using Evidence Intelligence™

Oral semaglutide reduces cardiovascular events in type 2 diabetes

Key finding

The risk of the primary outcome in the overall trial population was 14% lower for oral semaglutide versus placebo (hazard ratio, 0.86; 95% CI, 0.77–0.96).

This study evaluated the effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes, finding a 14% reduction in major adverse cardiovascular events compared to placebo.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Some Concerns bias

Last updated July 6, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Oral Semaglutide, Placebo

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Primary outcome

Time to first major adverse cardiovascular event

Comparator

Placebo

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study evaluated the effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes, finding a 14% reduction in major adverse cardiovascular events compared to placebo.

Clinical relevance

These findings are clinically significant as they suggest that oral semaglutide not only helps manage blood sugar levels in type 2 diabetes but also may lower the risk of serious cardiovascular events. This dual benefit could lead to better overall health outcomes for patients with diabetes, a population at high risk for heart disease.

Keep in mind

The study did not assess long-term cardiovascular outcomes beyond the trial duration. Findings may not be generalizable to all populations with type 2 diabetes. Subgroup analyses did not show significant interactions for several outcomes.

Published in

Journal Reference

Publication details and source links for this paper.

Nikolaus M, John ED, Johannes FM, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Circulation. 2025;151(23):1639-1650. doi:10.1161/CIRCULATIONAHA.125.074545

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Oral semaglutide reduced the risk of major adverse cardiovascular events by 14%.

Significant reduction in HbA1c levels was observed with oral semaglutide compared to placebo (p=0.05).

Body mass index decreased more with oral semaglutide than with placebo (p=0.05).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and Adverse events incidence, All-cause mortality, BMI, and 7 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Adverse events incidence

Evidence topic

Adverse Events and Safety

Primary intervention

Semaglutide

Primary outcomes

Adverse events incidence
All-cause mortality
BMI

Evidence topics

Adverse Events and Safety Cardiovascular Risk HbA1c Reduction Inflammatory and Vascular Markers

Primary intervention

Semaglutide

Primary outcomes

Adverse events incidence All-cause mortality BMI

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 10 evidence relationships
Includes primary outcome data
Linked to 6 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Semaglutide → Time to first nonfatal myocardial infarction event

Evidence profile

NoneNo ChangeClinical Outcomes

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Oral semaglutide showed a 14% reduction in major cardiovascular events.
HbA1c levels decreased by 0.66% with oral semaglutide (p=0.05).
BMI decreased by 1.5 kg/m² with oral semaglutide (p=0.05).

Who this applies to

Adults diagnosed with type 2 diabetes.
Patients at risk for cardiovascular events.

Keep in Mind

The study's results may not apply to patients without diabetes.
Effectiveness in diverse populations or those with comorbidities was not evaluated.
Long-term safety and efficacy of oral semaglutide require further investigation.

Between the Lines

The study did not assess long-term cardiovascular outcomes beyond the trial duration.
Findings may not be generalizable to all populations with type 2 diabetes.
Subgroup analyses did not show significant interactions for several outcomes.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Mass Index.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

GLP-1 Receptor AgonistsHbA1c

Medications

11 studies

Detailed evidence

GLP-1 Receptor AgonistsBody Mass Index

Medications

4 studies

Detailed evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

11 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

11 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Mass Index Evidence Hub

All studies measuring Body Mass Index

4 studies

outcome_hub

Measures Body Mass Index as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Moderate Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.8 | strong positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve cardiovascular outcomes?

Emerging Evidence

GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.

ConsensusScore™: Results are generally consistent across studies.

Ranked evidence signals

1
All-cause mortality
EvidenceScore™ Emerging | EvidenceScore™ 54.4 | weak positive | ConsensusScore™ Mixed | 1 study

Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body mass index?

Emerging Evidence

GLP-1 Receptor Agonists may improve Body Mass Index.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 55.2 | moderate positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve adipokine and angiogenic markers?

Emerging Evidence

GLP-1 Receptor Agonists appears to improve Adipokine and Angiogenic Markers.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
LDL cholesterol
EvidenceScore™ Limited | EvidenceScore™ 35.4 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 7 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Adverse Events and Safety Evidence Hub Cardiovascular Risk Evidence Hub HbA1c Reduction Evidence Hub Inflammatory and Vascular Markers Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Semaglutide and Adverse events incidence All studies on Semaglutide and HbA1c All studies on Semaglutide and BMI All studies on Semaglutide and All-cause mortality

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Higher semaglutide doses improve glucose control in type 2 diabetes Novel Semaglutide Injection Shows Non-Inferior Glycemic Control Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.Semaglutide cuts insulin needs in adults with type 1 diabetes and obesity

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.